Orbital Therapeutics, a business dedicated to improving global health by realizing the full potential of RNA therapies to cure human disease, announced today the successful completion of a $270 million Series A investment round.
ARCH Venture Partners led the Series A round, with participation from initial investors a16z Bio + Health and Newpath Partners, as well as new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and others.
Orbital Therapeutics aspires to broaden the application of RNA-based therapies across a wide spectrum of human disorders, including next-generation vaccinations, immunomodulation, and protein replacement.
The company is developing a unique RNA platform that combines established and upcoming RNA technologies and delivery modalities.
This technology is intended to increase the longevity of Orbital’s innovative RNA therapies while also broadening their distribution to a broader range of cell types and regions.
Ms. Subramanian has 25 years of business and corporate development experience, including leading multifunctional teams, managing partnerships and M&A transactions, and directing portfolio planning, alliance management, finance, and operations.
She most recently served as Rheos Medicines’ chief operating officer, and before that, she was senior vice president, corporate development and business planning at Agios Pharmaceuticals, where she oversaw numerous significant initiatives, including the $2 billion sale of Agios’ cancer division in December 2020.
She formerly worked at Novartis Vaccines as vice president, head of Influenza Global Programs, and as vice president, Vaccines Business transition lead following the divestiture of the business unit.Orbital Therapeutics seeks to improve world health by releasing the full potential of RNA-based therapeutics excluding tiny interfering RNA to cure human disease in previously unimaginable ways.
The business is developing a first-of-its-kind platform at the convergence of RNA technology, delivery techniques, data analytics, and automation in order to generate a broad portfolio of pharmaceuticals, initially focused on vaccinations, immunomodulation, and protein replacement.
Orbital was founded by professionals in genetic medicine, RNA development and delivery, and has an operational structure designed to harness the creativity of a large and diverse team of scientists, drug developers, and business leaders.
